These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17632858)

  • 1. [The first inhalational insulin. Which patients really profit from it? (interview by Dr. D. Einecke)].
    Schumm-Draeger PM
    MMW Fortschr Med; 2007 Jan; 149(1-2):16-7. PubMed ID: 17632858
    [No Abstract]   [Full Text] [Related]  

  • 2. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
    Crasto W; Jarvis J; Hackett E; Nayyar V; McNally PG; Davies MJ; Lawrence IG
    Postgrad Med J; 2009 Apr; 85(1002):219-22. PubMed ID: 19417173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whither inhaled insulin?
    Young B
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):413. PubMed ID: 16932324
    [No Abstract]   [Full Text] [Related]  

  • 5. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhaled insulin for diabetes mellitus.
    McMahon GT; Arky RA
    N Engl J Med; 2007 Feb; 356(5):497-502. PubMed ID: 17267909
    [No Abstract]   [Full Text] [Related]  

  • 9. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
    Hess R; Kerner W
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
    [No Abstract]   [Full Text] [Related]  

  • 10. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 11. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes.
    Goldstein HH
    Postgrad Med; 2008 Sep; 120(3):172-9. PubMed ID: 18824835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical and health economic review of a prefilled insulin pen.
    Niskanen L
    Curr Med Res Opin; 2010 Oct; 26(10):2431-9. PubMed ID: 20815660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming barriers to insulin replacement.
    Kuritzky L
    J Fam Pract; 2009 Aug; 58(8 Suppl):S25-31. PubMed ID: 19679028
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing insulin vials to pens--comparison of charges, not healthcare benefits.
    Thethi TK
    J Med Econ; 2013 Oct; 16(10):1228-30. PubMed ID: 23926888
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current cost analysis in the management of diabetes mellitus].
    Oberender P
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
    J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Currie CJ; Evans M; Poole CD
    Diabetes Obes Metab; 2008 Jan; 10(1):94-5. PubMed ID: 18095951
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
    Yang WY; Ji QH; Zhu DL; Yang JK; Chen LL; Liu ZM; Yu DM; Yan L
    Chin Med J (Engl); 2009 Jul; 122(14):1704-8. PubMed ID: 19719975
    [No Abstract]   [Full Text] [Related]  

  • 20. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes.
    Reimer T; Hohberg C; Pfützner AH; Jørgensen C; Jensen KH; Pfützner A
    Clin Ther; 2008 Dec; 30(12):2252-62. PubMed ID: 19167585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.